Siemens Healthineers: 3 factors that make the share a must-have

Siemens Healthineers: 3 factors that make the share a must-have

Siemens Healthineers started perfectly into 2021.Compared to the same period last year, sales rose by 13.3 % in the first quarter.Thanks to the Corona antigen fast tests in particular, the Diagnostics segment increased by 23.5 %.The result per share rose by 36 % to 0.49 euros.The Free Cashflow doubled to 668 million.Euro.These are all excellent numbers. Doch wie steht es um die Zukunftsperspektive? Können wir Foolishe Investoren noch guten Gewissens zugreifen? Aktuell notiert die Aktie bei 46,72Euro (Stand: 15.April 2021).

Siemens Healthineers has interesting problem solvers in the pipeline

On 12.April announced the company that its ATELLICA VTLI2 analysis system received CE certification.Management is still planning the market launch for spring 2021.

With the system, doctors receive a test result in laboratory quality for cardiac troponin I (HS-CTNI) within eight minutes.Cardiac troponins are protein building blocks that occur in the muscle cells of the heart muscles.After damage to the heart muscle, for example due to a heart attack, these protein fabrics occur more and more into the blood and can be measured there.

Siemens Healthineers is a pioneer in this technology.The added value for customers is high: Doctors can diagnose heart attacks precisely and safely.The patient's treatment can be initiated earlier than before.

Siemens Healthineers is also growing inorganically

A few weeks ago, the Siemens subsidiary emitted new shares for institutional investors.The largest package for 380 million.Euro an QIA, den Staatsfonds von Katar.

The bottom line was 2.3 billion.Euro in die Kassen des Konzerns, mit denen nun die Übernahme des Strahlentherapie-Spezialisten Varian Medical Systems im ersten Halbjahr 2021 abgeschlossen werden soll.Siemens Healthineers pays 13.7 billion for the US company.Euro.Management around CEO Bernd Montag sees potential, especially in the interaction of their own imaging devices with the cancer therapy applications of Varian.

CFIUS, the US control authority for foreign investments, had already released the acquisition last year.According to the regulators, there are no concerns about national security.

The takeover offers great synergy potential and can ensure increasing sales in the long term, because radiology is an attractively growing market.

A lot of music plays in medical technology

The industry is now more popular than ever and in my view almost a must-have for all investors.Modern technology is an important lever to get the rising costs under control in the health sector.Efficiency is the requirement of the hour.

But the sticking point is the distribution.Hospitals, medical practices, health insurance and the public sector have to convince that expensive initial investments will be profitable on a long distance.The consideration of minimizing the cost factor sales may also have been behind the following idea.

Siemens Healthineers checks the ultrasound division

According to the first estimates, the possible sales proceeds at 840 million should.Euro liegen.Possible customers would be financial investors, but also direct competitors.

The ultrasound business at Siemens Healthineers is currently part of the profitable "Imaging" segment.This generated 8.8 billion in the 2020 financial year.Euro 61 % des Gesamtumsatzes.However, the subsequent segment "Ultrasound" only plays a small role here.The business here is very small, since the devices are used not only in hospitals and radiology centers, but also in medical practices.

With the sale, Siemens Healthineers could tighten the complex sales and thus continue to turn the efficiency screw.In the industry comparison, margins are already absolutely competitive, as the following table shows.

The margins in the Peergroup of Siemens Healthineers in the past twelve months



Gruttom margin in %

EBT margin in %

Nettoma in %

Siemens Healthineers

Siemens Healthineers: 3 Faktoren, die die Aktie zum Must-have machen





Abbott Laboratories











The stock is very interesting

The Siemens spin-off has positioned itself very well for the future.On his way of consolidation, Siemens Healthineers slowly sees light at the end of the tunnel.Compared to Siemens Energy (WKN; ENER6Y), a somewhat newer branch of the German industrial divider, I see the future for the medical technology division much rosier.

Around 46 million have been.New shares emitted.And Siemens Healthineers will surely need further capital in the coming years.But the financing conditions are cheap and rare.And thanks to the takeover of Varian, there is interesting potential for the future.

Mit aktuell 46,72Euro ist die Aktie nahezu fair bewertet.The price-profit ratio is 31, the course sales ratio at 3 and the course book value ratio at 4.With a view to the lively growth market, however, the question arises as to whether the stock will be more favorable in the near future.I seriously consider getting in.

The article Siemens Healthineers: 3 factors that make the share a must-have was first published on The Motley Fool Germany.

Our 3 top shares for the post-covid era

The corona crisis also has an end. Für diese Phase sind einige company besonders gut gerüstet.

Unsere Analysten sind von drei company begeistert, und denken, dass sie fantastische Investitionen für die Post-Covid Ära sind.And that many investors do not yet have the shares on the radar.

You can download all information about these top shares here for free

Henning Lindhoff has none of the types mentioned.The Motley Fool has none of the stocks mentioned.

Motley Fool Germany 2021